Lenacapavir, a twice-yearly injection that offers near-total protection against HIV, will now be available for $40 per patient a year, in 120 low- and middle-income countries.
Lenacapavir, a twice-yearly injection that offers near-total protection against HIV, will now be available for $40 per patient a year, in 120 low- and middle-income countries.
Lenacapavir will still cost $28,000 a year in the US.
Patents should allow the first generic versions of Semaglutide (Ozempic) to appear next year. Again in low income countries, not developed nations.
Are we going to see a future trend of poorer countries bettering developed countries in health outcomes?